Lexaria Bioscience (LEXX) Insider Trading & Ownership $0.89 +0.00 (+0.49%) Closing price 03:58 PM EasternExtended Trading$0.89 0.00 (0.00%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Lexaria Bioscience (NASDAQ:LEXX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage26.40%Number OfInsiders Buying(Last 12 Months)5Amount OfInsider Buying(Last 12 Months)$100.20KNumber OfInsiders Selling(Last 12 Months)0 Get LEXX Insider Trade Alerts Want to know when executives and insiders are buying or selling Lexaria Bioscience stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LEXX Insider Buying and Selling by Quarter Lexaria Bioscience Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/30/2025Christopher BunkaDirectorBuy11,900$0.91$10,829.00 7/29/2025Christopher BunkaDirectorBuy15,600$0.92$14,352.00 7/29/2025John Martin DochertyInsiderBuy5,376$0.93$4,999.68 7/29/2025Richard ChristopherCEOBuy15,000$0.91$13,650.00 7/29/2025Vanessa CarleInsiderBuy750$0.91$682.50 7/29/2025William Edward MckechnieDirectorBuy5,000$0.91$4,550.00 12/2/2024Richard ChristopherCEOBuy22,828$2.24$51,134.72 (Data available from 1/1/2013 forward) LEXX Insider Trading Activity - Frequently Asked Questions Who is on Lexaria Bioscience's Insider Roster? The list of insiders at Lexaria Bioscience includes Catherine C Turkel, Christopher Bunka, John Martin Docherty, Richard Christopher, Vanessa Carle, and William Edward Mckechnie. Learn more on insiders at LEXX. What percentage of Lexaria Bioscience stock is owned by insiders? 26.40% of Lexaria Bioscience stock is owned by insiders. Learn more on LEXX's insider holdings. Which Lexaria Bioscience insiders have been buying company stock? The following insiders have purchased LEXX shares in the last 24 months: Catherine C Turkel ($5,008.00), Christopher Bunka ($25,181.00), John Martin Docherty ($4,999.68), Richard Christopher ($64,784.72), Vanessa Carle ($682.50), and William Edward Mckechnie ($4,550.00). How much insider buying is happening at Lexaria Bioscience? Insiders have purchased a total of 78,054 LEXX shares in the last 24 months for a total of $105,205.90 bought. Which Lexaria Bioscience insiders have been selling company stock? The following insider sold LEXX shares in the last 24 months: Vanessa Carle ($10,268.00). How much insider selling is happening at Lexaria Bioscience? Insiders have sold a total of 2,567 Lexaria Bioscience shares in the last 24 months for a total of $10,268.00 sold. Lexaria Bioscience Key ExecutivesMr. Christopher A. Bunka (Age 62)Chairman & CEO Compensation: $291.19k2 recent tradesMr. John M. Docherty M.Sc. (Age 55)President & Director Compensation: $290.46kMr. Nelson D. Cabatuan CPA (Age 45)Chief Financial Officer Kristin HamiltonDirector of OperationsVanessa CarleHead of Legal1 recent tradesDr. Philip N. Ainslie Ph.D.Advisor & Consultant More Insider Trading Tools from MarketBeat Related Companies Werewolf Therapeutics Insider Ownership Precision BioSciences Insider Ownership Invizyne Technologies Insider Ownership ImageneBio Insider Ownership Clene Insider Ownership Karyopharm Therapeutics Insider Ownership NRx Pharmaceuticals Insider Ownership Verrica Pharmaceuticals Insider Ownership vTv Therapeutics Insider Ownership Lantern Pharma Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:LEXX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredSell this, buy thatI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access